Literature DB >> 19123894

Neuroimaging and quality-of-life outcomes in patients with brain metastasis and peritumoral edema who undergo Gamma Knife surgery.

Hung-Chuan Pan1, Ming-Hsih Sun, Clayton Chi-Chang Chen, Chun-Jung Chen, Chen-Hui Lee, Jason Sheehan.   

Abstract

OBJECT: Gamma Knife surgery (GKS) has been shown to be effective for treating many patients with brain metastasis. Some brain metastases demonstrate significant peritumoral edema; radiation may induce cerebral edema or worsening preexisting edema. This study was conducted to evaluate the imaging and neurobehavioral outcomes in patients with preexisting peritumoral edema who then undergo GKS.
METHODS: Between August 2003 and January 2008, 63 cases of brain metastasis with significant peritumoral edema (> 20 cm(3)) were prospectively studied. The study inclusion criteria were as follows: 1) a single metastatic lesion with significant edema (perilesional edema signal volume on FLAIR > 20 cm(3)); and 2) inclusion of only 1 lesion > 20 cm(3) in the study (in cases of multiple lesions noted on FLAIR images). All patients received MR imaging with pulse sequences including T1-weighted imaging and FLAIR with or without contrast and T2-weighted imaging at an interval of 3 months. A neurological assessment and Brain Cancer Module (BCM-20) questionnaire were obtained every 2-3 months. Kaplan-Meier, Cox regression, and logistic regression were used for analysis of survival and associated factors.
RESULTS: At the time of GKS, the median Karnofsky Performance Scale (KPS) score was 70 (range 50-90), and the mean BCM-20 score was 45.5 +/- 6.1. The mean tumor volume (+/- standard deviation) was 5.2 +/- 4.6 cm(3) with corresponding T2-weighted imaging and FLAIR volumes of 59.25 +/- 37.3 and 62.1 +/- 38.8 cm(3), respectively (R(2) = 0.977, p < 0.001). The mean edema index (volume of peritumoral edema/tumor volume) was 17.5 +/- 14.5. The mean peripheral and maximum GKS doses were 17.4 +/- 2.3 and 35 +/- 4.7 Gy, respectively. The median survival was 11 months. The longer survival was related to KPS scores >or= 70 (p = 0.008), age < 65 years (p = 0.022), and a reduction of > 6 in BCM-20 score (p = 0.007), but survival was not related to preexisting edema or tumor volume. A reduction in BCM-20 score of > 6 was related to decreased volume in T1-weighted and FLAIR imaging (p < 0.001). Thirty-eight (79.2%) of 48 patients demonstrated decreased tumor volume and accompanied by decreased T2-weighted imaging and FLAIR volume. Eight (16.7%) of the 48 patients exhibited increased or stable tumor volume. A margin dose > 18 Gy was more likely to afford tumor reduction and resolution of peritumoral edema (p = 0.005 and p = 0.006, respectively). However, prior external-beam radiation therapy correlated with worsened preexisting peritumoral edema (p = 0.013) and longer maintenance of corticosteroids (p < 0.001).
CONCLUSIONS: Patients demonstrating a reduction in the BCM-20 score > 6, age < 65 years, and KPS score >or= 70 exhibited longer survival. Significant preexisting edema did not influence the tumor response or clinical outcome. The resolution of edema was related to better quality of life but not to longer survival.

Entities:  

Mesh:

Year:  2008        PMID: 19123894     DOI: 10.3171/JNS/2008/109/12/S15

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  8 in total

1.  Outcome of partially irradiated recurrent nonfunctioning pituitary macroadenoma by gamma knife radiosurgery.

Authors:  Chiung-Chyi Shen; Weir-Chiang You; Ming-Hsi Sun; Shinh-Dung Lee; Hsi-Kai Tsou; Yen-Ju Chen; Meei-Ling Sheu; Jason Sheehan; Hung-Chuan Pan
Journal:  J Neurooncol       Date:  2018-06-13       Impact factor: 4.130

Review 2.  A comprehensive review of MR imaging changes following radiosurgery to 500 brain metastases.

Authors:  T R Patel; B J McHugh; W L Bi; F J Minja; J P S Knisely; V L Chiang
Journal:  AJNR Am J Neuroradiol       Date:  2011-09-15       Impact factor: 3.825

3.  Post-radiosurgical edema associated with parasagittal and parafalcine meningiomas: a multicenter study.

Authors:  Jason P Sheehan; Or Cohen-Inbar; Rawee Ruangkanchanasetr; S Bulent Omay; Judith Hess; Veronica Chiang; Christian Iorio-Morin; Michelle Alonso-Basanta; David Mathieu; Inga S Grills; John Y K Lee; Cheng-Chia Lee; L Dade Lunsford
Journal:  J Neurooncol       Date:  2015-09-02       Impact factor: 4.130

4.  A new strategy of CyberKnife treatment system based radiosurgery followed by early use of adjuvant bevacizumab treatment for brain metastasis with extensive cerebral edema.

Authors:  Yang Wang; Enmin Wang; Li Pan; Jiazhong Dai; Nan Zhang; Xin Wang; Xiaoxia Liu; Guanghai Mei; Xiaofang Sheng
Journal:  J Neurooncol       Date:  2014-05-31       Impact factor: 4.130

5.  Based on arterial spin labeling helps to differentiate high-grade gliomas from brain solitary metastasis: A systematic review and meta-analysis.

Authors:  Min Fu; Fang Han; Changchao Feng; Tao Chen; Xiaobo Feng
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

6.  Outcome of intracerebral cavernoma treated by Gamma Knife radiosurgery based on a double-blind assessment of treatment indication.

Authors:  Chiung-Chyi Shen; Meei-Ling Sheu; Ming Hsi Sun; Meng-Yin Yang; Weir-Chiang You; Yen-Ju Chen; Ying Ju Chen; Jason Sheehan; Hung-Chuan Pan
Journal:  Radiat Oncol       Date:  2021-08-28       Impact factor: 3.481

7.  Differentiation of malignant brain tumor types using intratumoral and peritumoral radiomic features.

Authors:  Dongming Liu; Jiu Chen; Honglin Ge; Xinhua Hu; Kun Yang; Yong Liu; Guanjie Hu; Bei Luo; Zhen Yan; Kun Song; Chaoyong Xiao; Yuanjie Zou; Wenbin Zhang; Hongyi Liu
Journal:  Front Oncol       Date:  2022-07-28       Impact factor: 5.738

8.  Pseudoprogression and peritumoral edema due to intratumoral necrosis after Gamma knife radiosurgery for meningioma.

Authors:  In-Ho Jung; Kyung Won Chang; So Hee Park; Hyun Ho Jung; Jong Hee Chang; Jin Woo Chang; Won Seok Chang
Journal:  Sci Rep       Date:  2022-08-11       Impact factor: 4.996

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.